Navigation Links
Receptors involved in corneal clarity identified

The researchers at the Aberdeen University have found out molecules that could aid in the treatment of cancer, heart diseases and other serious disorders//.

The expression of this molecule, sflt-1, a free-floating receptor for vascular endothelial growth factor A, prevents the formation of vision obstructing blood vessels, thus keeps the cornea clear.

According to the researchers, this discovery could help in the development of new drugs, new therapies for eye diseases and eye injuries. The Aberdeen team and colleagues at the Medical College of Georgia and the University of Kentucky in the US conducted this research.

Dr Martin Collinson, senior lecturer at the University of Aberdeen, said, "The molecule is an amazing finding". He added: "The cornea is widely used by scientists who hope to study how blood vessels grow or how to inhibit the growth of new blood vessels. "This knowledge will help to treat diseases like cancer, heart disease, rheumatoid arthritis, stroke and eye disorders like macular degeneration. "The cornea is our window on the world. If it contained blood vessels it would not be transparent and we would not be able to see. "If you study a normal eye you will see blood vessels in the whites of the eye but these stop at the cornea."

The cornea could get vascularised or form blood vessels due to disease or injury. Tumors are able to grow due to their capacity to attract blood vessels. Hence, vascularisation is crucial in diseases like cancer.
GYT
'"/>




Page: 1

Related medicine news :

1. Effects Of Certain Food Related To Single Pain Receptors
2. Inhibitor That Blocks Host Receptors Found To be Effective In Treating Anthrax
3. Max Planck Researchers Incorporate Odorant Receptors into Artificial Membranes
4. Nitric oxide involved in high blood pressure
5. Scientists locate key hormone involved in appetite control
6. Risks involved in Procedural Sedation
7. Toxin causing Gastrointestinal problems identified
8. Gene Variant associated with Schizophrenia identified
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/24/2017)... ... August 24, 2017 , ... Lori ... the development and advances in Desensitization therapy to improve the outcomes of organ ... about his remarkable journey of his 25 years of research in developing therapies ...
(Date:8/24/2017)... ... August 24, 2017 , ... Prime candidates for home ... have a condition that needs further monitoring such as surgery, stroke, heart attack ... stable, such as diabetes, high blood pressure, heart/lung disease, arthritis and stroke. ...
(Date:8/23/2017)... ... 2017 , ... The Arc Mercer, Capitol County’s premier provider of programs and ... community organization for people with special needs. The group, the Special Needs Alliance for ... of New Jersey – but the first in the entire country! , SNAP was ...
(Date:8/23/2017)... ... 2017 , ... Drs. Steven White and Brad Haines are pleased to announce ... of this offer, valued at more than $300 per year, new patients can enjoy ... patients receive a complimentary professional whitening procedure. , Stained or yellowed tooth enamel ...
(Date:8/23/2017)... ... ... Awards have announced the winners of the Best of the IBA Awards in The 2017 ... in the 2017 IBAs were not able to apply for the Best of the IBA ... awards won in the IBAs with a Gold Stevie win counting for three points, a ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017   Mostyn Law and Gulf Coast Regional Blood ... . The Mostyn Law family has had 3 ... is why Mostyn Law is partnering with Gulf Coast ... its appreciation. Blood supplies are running low. Gulf Coast ... hospital needs in August. That is why the blood center reached ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that ... Therapy Inc., has recently opened a New York City Office in ... usage of its unique Topical Wound Oxygen (TWO 2 ) homecare ... the Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS ... ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
Breaking Medicine Technology: